Emergent BioSolutions | EBS - Loan Capital


Emergent BioSolutions reported $446.5M in Loan Capital for its fiscal quarter ending in December of 2023.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 24.75M 11.64M Jun/2026
ALKERMES USD 1.48B 7.23M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
ANI Pharmaceuticals USD 280.15M 5.84M Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Myriad Genetics USD 120.7M 400K Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024